MEDPLUS HEALTH SERVICES LTD.
NSE : MEDPLUSBSE : 543427ISIN
CODE : INE804L01022Industry : Pharmaceuticals & DrugsHouse
: Private
BSE700.1510.05 (+1.46 % )
PREV CLOSE (Rs.) 690.10
OPEN PRICE (Rs.) 685.05
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 330
TODAY'S LOW / HIGH (Rs.)
52 WK LOW / HIGH (Rs.)
NSE701.00 12.1 (+1.76 % )
PREV CLOSE(Rs.) 688.90
OPEN PRICE (Rs.) 689.90
BID PRICE (QTY) 698.85 (16 )
OFFER PRICE (QTY) 700.90 (10 )
VOLUME 2329
TODAY'S LOW / HIGH(Rs.)
52 WK LOW / HIGH (Rs.)
Company News
| Date | Heading | Details |
|---|---|---|
| 26-Mar-2024 | Medplus Health Services informs about revised disclosure | <p style="text-align: justify;">Medplus Health Services has informed that the exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on March 23, 2024 for Madhukar Reddy Gangadi.</p><div>The above information is a part of company's filings submitted to BSE.</div> |
| 23-Mar-2024 | Medplus Health Services informs about disclosures | <div style="text-align: justify;">Medplus Health Services has informed that the Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on March 23, 2024 for Agilemed Investments.</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</div> |
| 23-Mar-2024 | Medplus Health Services informs about revised disclosure | <p style="text-align: justify;">Medplus Health Services has informed that the exchange has received the revised Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on March 23, 2024 for Madhukar Reddy Gangadi.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p> |
| 06-Mar-2024 | Medplus Health Services informs about analyst meet | <div>Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Medplus Health Services has informed that schedule of Analyst/Institutional Investor Meet meeting to be held on Thursday, March 7, 2024 is submitted.</div><div><br></div><div>The above information is a part of company's filings submitted to BSE.</div><div><br></div> |
| 02-Mar-2024 | Medplus Health Services informs about disclosure | <div style="text-align: justify;">Medplus Health Services has informed that one of the subsidiary of the Company, Optival Health Solutions has received a suspension order from Drugs and Control authorities, under Drugs and Cosmetic Act, 1940 read with rules made thereunder for temporarily suspending the operations of store as mentioned in the table enclosed. Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 details are enclosed.</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</div><div style="text-align: justify;"><br></div> |
| 01-Mar-2024 | Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015. | One of our subsidiary has received order from Assistant Director and Drug Control Administration. Detail disclosure is enclosed. |
| 21-Feb-2024 | Medplus Health Services informs about outcome of board meeting | <div>Medplus Health Services has informed that the Board of Director at its meeting held today, February 21, 2024 decided the followings: Diagnostic Business: Defer the expansion plans for Diagnostics Division beyond Hyderabad, until the profitability of the pilot project is established; Pharmacy Business: Expansion of Pharmacy business through internal accruals and working capital loan etc. Considering the above, the Board has decided not to proceed with the fund-raising approval received from the shareholders on November 30, 2023. The meeting of the Board of Directors started at 11:30 PM and concluded at 12.05 PM.</div><div><br></div><div>The above information is a part of company's filings submitted to BSE.</div><div><br></div> |
| 17-Feb-2024 | Medplus Health Services informs about disclosure | <p style="text-align: justify;">Medplus Health Services has informed that the exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on February 16, 2024 for Lone Furrow Investments.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE. </p> |
| 17-Feb-2024 | Medplus Health Services informs about disclosures | <div style="text-align: justify;">Medplus Health Services has informed that it enclosed Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on February 16, 2024 for Lone Furrow Investments.</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</div> |
| 16-Feb-2024 | QIP Announcement | Inter alia, to discuss the management recommendation to not proceed with the approval for Qualified Institutional Placement (QIP) received from shareholders on November 30, 2023. |
